Chemours (NYSE:CC) Stock Moved Down to “Hold” by Mizuho

Chemours (NYSE:CC) was downgraded by equities researchers at Mizuho from a “strong-buy” rating to a “hold” rating in a report issued on Tuesday, Zacks reports.

CC has been the topic of several other reports. BMO Capital Markets cut their target price on Chemours from $26.00 to $18.00 and set an “outperform” rating on the stock in a research note on Thursday, August 13th. Truist Financial dropped their price objective on Chemours from $30.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Royal Bank Of Canada cut Chemours from an “outperform” rating to a “sector perform” rating and set a $14.00 price objective for the company. in a report on Tuesday. Zacks Research upgraded Chemours from a “strong sell” rating to a “hold” rating in a research report on Thursday, September 10th. Finally, JPMorgan Chase & Co. reduced their target price on Chemours from $22.00 to $15.00 and set a “neutral” rating on the stock in a research note on Thursday, August 13th. Three research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $18.09.

Chemours Price Performance

Shares of Chemours stock opened at $12.81 on Tuesday. The company’s fifty day simple moving average is $14.79 and its two-hundred day simple moving average is $18.97. Chemours has a 12-month low of $10.44 and a 12-month high of $28.67. The firm has a market cap of $1.93 billion, a PE ratio of -6.71 and a beta of 1.41. The company has a quick ratio of 0.88, a current ratio of 1.66 and a debt-to-equity ratio of 18.98.

Chemours (NYSE:CC) last issued its quarterly earnings data on Tuesday, August 4th. The specialty chemicals company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.07). The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.65 billion. Chemours had a negative net margin of 5.00% and a positive return on equity of 60.64%. The business’s revenue was down 1.5% on a year-over-year basis. During the same period last year, the company posted ($2.54) earnings per share. As a group, equities analysts expect that Chemours will post 0.84 EPS for the current year.

Insider Transactions at Chemours

In related news, CFO Shane Hostetter bought 3,350 shares of the company’s stock in a transaction dated Thursday, August 6th. The stock was purchased at an average cost of $14.94 per share, with a total value of $50,049.00. Following the transaction, the chief financial officer owned 102,698 shares in the company, valued at approximately $1,534,308.12. This trade represents a 3.37% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Calderon Gerardo Familiar bought 1,935 shares of the business’s stock in a transaction dated Wednesday, August 12th. The shares were bought at an average cost of $15.53 per share, for a total transaction of $30,050.55. Following the purchase, the insider directly owned 58,547 shares in the company, valued at approximately $909,234.91. This represents a 3.42% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders purchased 8,663 shares of company stock valued at $130,601. Company insiders own 0.85% of the company’s stock.

Institutional Trading of Chemours

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Chemours during the 2nd quarter worth approximately $34,000. Allworth Financial LP bought a new position in shares of Chemours in the 2nd quarter worth approximately $51,000. State of Wyoming bought a new position in shares of Chemours in the 2nd quarter worth approximately $67,000. Nykredit A S bought a new position in shares of Chemours in the 2nd quarter worth approximately $99,000. Finally, Parallel Advisors LLC lifted its stake in shares of Chemours by 10.9% in the 1st quarter. Parallel Advisors LLC now owns 5,366 shares of the specialty chemicals company’s stock valued at $118,000 after purchasing an additional 527 shares during the period. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: BMO Capital reaffirmed its Buy rating, indicating that some analysts still see recovery potential in Chemours despite the recent weakness. BMO Capital reaffirms Buy rating
• Neutral Sentiment: Barclays initiated coverage at Equal Weight, while Mizuho maintained a Neutral rating but reduced its price target to $15 from $18. The new target still implies potential upside from recent trading levels, but the cut signals more cautious expectations. Mizuho downgrades Chemours
• Negative Sentiment: RBC Capital downgraded Chemours to Sector Perform from Outperform and cut its price target to $14 from $22, citing persistent TiO₂ weakness, soft chemical demand and potential headwinds in the Thermal & Specialized Solutions segment through year-end. RBC downgrades Chemours
• Negative Sentiment: Several law firms announced or promoted a securities-fraud class action filed against Chemours and certain officers. The case covers investors who purchased shares from February 20 through August 4, 2026, and alleges investors were harmed by disclosures concerning Opteon refrigerant aftermarket demand. The lead-plaintiff deadline is December 7, 2026. Although the allegations have not been proven, the litigation creates legal, financial and reputational risks. Chemours securities-fraud class action

Chemours Company Profile

The Chemours Company (NYSE: CC) is a global chemical company that develops, manufactures and distributes specialty chemical products used in a range of industrial and consumer applications. Its portfolio serves markets including coatings, plastics, automotive, refrigeration and air conditioning, electronics, telecommunications, energy, healthcare and general manufacturing.

Chemours operates through three primary business segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials.